HCCs are highly vascularized tumors, which often develop an arterialized blood supply that feeds tumor progression.3 Sorafenib—a broad tyrosine kinase inhibitor (TKI) with potent antivascular endothelial growth factor receptor (VEGFR)1–3 and platelet-derived growth factor receptor (PDGFR) activity—was the first systemic therapy to show increased overall survival (OS) in patients with advanced HCC in phase III trials.4 5 However, HCCs become resistant to sorafenib and the OS benefit is limited to approximately 3 months over placebo. Here, PDGFRB is linked to hepatocellular carcinoma.